Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

Eri Kawata, MDPhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Alejandro Lazo-Langner, MDMSc, Michael Levy, PhD, Stephanie Santos, Hanxin Lin, PhD, Chris Howlett, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-138654

Published: 2020

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Donna L. Forrest, MD, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Mary-Margaret Keating, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-136163

Published: 2020

Journal Articles

Efficacy of Oral Ribavirin in Respiratory Syncytial Virus Infection in Hematopoietic Stem Cell Transplant Patients: A Single-Centre Experience

Shona Philip, BSc, MD, Adrienne Fulford, NP,MSN, Krista Biederman, BScPhm, Brandon Dorland, NP, MSN, Anargyros Xenocostas, MD FRCPC, Uday Deotare, MBBS, MD DM

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142888

Published: 2020

Journal Articles

Excellent Outcomes in Patients with Primary and Secondary Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using a Rituximab, Busulfan, Melphalan, Thiotepa Conditioning Regimen

Shona Philip, BSc, MD, Adrienne Fulford, NP,MSN, Selay Lam, MDBSc,FRCPC, Chai Wye Phua, MD FRCPC, Joy Mangel, MD FRCPC, Kang Howson-Jan, MD FRCPC, Brandon Dorland, NP, MSN, Karen Atkinson, NP, MSN, Anargyros Xenocostas, MD FRCPC, Uday Deotare, MBBS, MD DM

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-139635

Published: 2020

Journal Articles

Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?

Eri Kawata, MDPhD, Benjamin Hedley, PhD, Benjamin Chin-Yee, MD, Anargyros Xenocostas, MD FRCPC, Alejandro Lazo-Langner, MDMSc, Cyrus C. Hsia, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Ping Yang, PhD DABMGG, Michael Levy, PhD, Stephanie Santos, Chris Howlett, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138667

Published: 2020

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Dennis Dong Hwan Kim, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2019) 134 (Supplement_1): 1644.

https://doi.org/10.1182/blood-2019-128283

Published: 2019

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

The Clinical Application of Oncomine Myeloid Next Generation Sequencing (NGS): Comparison of Cytogenetics and NGS in Patients with Suspected Myelodysplastic Syndrome

Eri Kawata, MD PhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Uday Deotare, MBBS, MD DM, Lalit Saini, MD, Ping Yang, PhD DABMGG, Michael Levy, PhD, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2019) 134 (Supplement_1): 3375.

https://doi.org/10.1182/blood-2019-126893

Published: 2019

Journal Articles

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

Eri Kawata, MD PhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Alejandro Lazo-Langner, MD MSc, Kang Howson-Jan, MD FRCPC, Uday Deotare, MBBS, MD DM, Lalit Saini, MD, Benjamin Hedley, PhD, Ping Yang, PhD DABMGG, Michael Levy, PhD, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2019) 134 (Supplement_1): 3438.

https://doi.org/10.1182/blood-2019-128507

Published: 2019

Journal Articles

The Predictive Value of Intracellular Imatinib Levels in Chronic Myeloid Leukemia

Nicholas L Jackson Chornenki, BSc, Christopher M. Hillis, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Caroline Hamm, MD, Wanda Hasegawa, MD, Jeffrey H. Lipton, MD PhD, Lynn Savoie, MD, Robert Turner, MD, Anargyros Xenocostas, MD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2018) 132 (Supplement 1): 4250.

https://doi.org/10.1182/blood-2018-99-111294

Published: 2018

Journal Articles

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial

Dennis Dong Hwan Kim, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, Stephen Couban, MDBSc, Robert Delage, MD, Anargyros Xenocostas, MD, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2018) 132 (Supplement 1): 787.

https://doi.org/10.1182/blood-2018-99-114656

Published: 2018

Journal Articles

Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia

Alejandro Garcia-Horton, MD, Rosanne St. Bernard, MD, Alejandro Lazo-Langner, MD MSc, Anargyros Xenocostas, MD, Joy Mangel, MD FRCPC, Kang Howson-Jan, MD FRCPC, Selay Lam, MDBSc, FRCPC, Cyrus C. Hsia, MDBSc, FRCPC

Blood (2018) 132 (Supplement 1): 5560.

https://doi.org/10.1182/blood-2018-99-120129

Published: 2018

Journal Articles

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Dennis Kim, MD, Isabelle Bence-Bruckler, Donna L Forrest, MD, Lynn Savoie, Stephen Couban, MDBSc, Lambert Busque, MD, Robert Delage, Pierre Laneuville, MD FRCPC, Elena Liew, MDBSc,FRCPC, Anargyros Xenocostas, MD, Kristjan Paulson, MD, Suzanne Kamel-Reid, Jeffrey H. Lipton, PhD MD FRCPC, Brian Leber, MD

Blood (2017) 130 (Supplement 1): 1622.

https://doi.org/10.1182/blood.V130.Suppl_1.1622.1622

Published: 2017

Journal Articles

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD PhD, Isabelle Bence-Bruckler, MD FRCPC, Donna L. Forrest, MD, Mary Lynn Savoie, MD, Stephen Couban, MD, Lambert Busque, MD PhD FRCPC, Robert Delage, MD MSc, FRCP, Pierre Laneuville, MD FRCPC, Elena Liew, MD, Anargyros Xenocostas, MD, Kristjan Paulson, MD FRCPC, Suzanne Kamel-Reid, PhD DABMG, FACMG, Jeff H. Lipton, MD PhD, Brian Leber, MD

Blood (2016) 128 (22): 1922.

https://doi.org/10.1182/blood.V128.22.1922.1922

Published: 2016

Journal Articles

Erythropoiesis-Stimulating Agents in Elderly Patients with Anemia of Unknown Etiology: Treatment Response and Cardiovascular Outcomes

Zachary Gowanlock, BASc, Swetha Sriram, MD, Alison Martin, MD, Anargyros Xenocostas, MD, Alejandro Lazo-Langner, MD MSc, FRCPC

Blood (2016) 128 (22): 1267.

https://doi.org/10.1182/blood.V128.22.1267.1267

Published: 2016

Journal Articles

Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds

Jason Tay, MDFRCPC MSc, David S. Allan, MD FRCPC, Elizabeth Chatelain, Doug Coyle, Mohamed Elemary, MD MSc,PhD, William Petrcich, Timothy Ramsay, Alan Tinmouth, MD FRCPC, Irwin Walker, MBBS, Anargyros Xenocostas, MD, Dean Fergusson, MHA, PhD

Blood (2016) 128 (22): 1032.

https://doi.org/10.1182/blood.V128.22.1032.1032

Published: 2016

Journal Articles

Erythropoietin in Elderly Patients with Anemia of Unknown Etiology

Zachary Gowanlock, BASc, Swetha Sriram, MD, Alison Martin, MD, Anargyros Xenocostas, MD FRCPC, Alejandro Lazo-Langner, MD MSc

Blood (2015) 126 (23): 3346.

https://doi.org/10.1182/blood.V126.23.3346.3346

Published: 2015

Journal Articles

Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia

Matthew Kang, BHSc, MD FRCPC, Anargyros Xenocostas, MD FRCPC, Alejandro Lazo-Langner, MD MSc, Ian H. Chin-Yee, MD FRCPC, Kang Howson-Jan, MD, Maisam Abouzeenni, BHSc, Michael J. Kovacs, MD FRCPC, Cyrus C. Hsia, BSc, MD FRCPC

Blood (2014) 124 (21): 5527.

https://doi.org/10.1182/blood.V124.21.5527.5527

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Efficacy of Oral Ribavirin in Respiratory Syncytial Virus Infection in Hematopoietic Stem Cell Transplant Patients: A Single-Centre Experience

Excellent Outcomes in Patients with Primary and Secondary Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using a Rituximab, Busulfan, Melphalan, Thiotepa Conditioning Regimen

Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

The Clinical Application of Oncomine Myeloid Next Generation Sequencing (NGS): Comparison of Cytogenetics and NGS in Patients with Suspected Myelodysplastic Syndrome

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

The Predictive Value of Intracellular Imatinib Levels in Chronic Myeloid Leukemia

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial

Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia

Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2 nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Erythropoiesis-Stimulating Agents in Elderly Patients with Anemia of Unknown Etiology: Treatment Response and Cardiovascular Outcomes

Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds

Erythropoietin in Elderly Patients with Anemia of Unknown Etiology

Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only